317
Participants
Start Date
October 3, 2012
Primary Completion Date
July 11, 2018
Study Completion Date
May 20, 2022
Lenalidomide and GA101
1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
institut Jules Bordet, Brussels
Université Catholique de Louvain Saint Luc, Brussels
ZNA Stuivenberg, Antwerp
CHU de Liège, Liège
Université Catholique de Louvain Mont Godinne, Yvoir
A.Z. Sint Jan AV, Bruges
AZ Groeninge - Campus Maria's Voorzienigheid, Kortrijk
Institut Paoli Calmette, Marseille
Institut d'Hématologie de Basse Normandie, Caen
CHU de Dijon, Dijon
Institut Bergonié, Bordeaux
Centre François Magendie, Pessac
CHU St Eloi, Montpellier
CHU Pontchaillou, Rennes
CHU de Grenoble, Grenoble
CHU Hôtel Dieu, Nantes
CHU Brabois, Nancy
CHRU de Lille, Lille
CHU d'Estaing, Clermont-Ferrand
Centre Léon Bérard, Lyon
CH Lyon Sud, Pierre-Bénite
Hôpital St Louis, Paris
Centre henri Becquerel, Rouen
CHU d'Amiens, Amiens
Hôpital Henri Mondor, Créteil
The Lymphoma Academic Research Organisation
OTHER